Generation of therapeutic antisera for emerging viral infections by Schmidt, Rebecca et al.
ARTICLE OPEN
Generation of therapeutic antisera for emerging viral infections
Rebecca Schmidt1, Lea C. Beltzig1, Bevan Sawatsky 1,2, Olga Dolnik2,3, Erik Dietzel2,3, Verena Krähling2,3, Asisa Volz2,4, Gerd Sutter2,4,
Stephan Becker2,3 and Veronika von Messling 1,2
The recent Ebola virus outbreak has highlighted the therapeutic potential of antisera and renewed interest in this treatment
approach. While human convalescent sera may not be readily available in the early stages of an outbreak, antisera of animal origin
can be produced in a short time frame. Here, we compared adjuvanted virus-like particles (VLP) with recombinant modiﬁed vaccinia
virus Ankara and vesicular stomatitis virus (VSV), both expressing the Ebola virus antigens. The neutralizing antibody titers of rabbits
immunized with adjuvanted VLPs were similar to those immunized with the replication-competent VSV, indicating that
presentation of the antigen in its native conformation rather than de novo antigen expression is essential for production of
functional antibodies. This approach also yielded high-titer antisera against Nipah virus glycoproteins, illustrating that it is
transferable to other virus families. Multiple-step immunoglobulin G puriﬁcation using a two-step 20–40% ammonium sulfate
precipitation followed by protein A afﬁnity chromatography resulted in 90% recovery of functionality and sustained in vivo stability.
Adjuvanted VLP-based immunization strategies are thus a promising approach for the rapid generation of therapeutic antisera
against emerging infections.
npj Vaccines  (2018) 3:42 ; doi:10.1038/s41541-018-0082-4
INTRODUCTION
Outbreaks of emerging viruses occur with worrying regularity, and
while some are quickly controlled locally, others become public
health events of global concern. Among the pathogens involved,
viruses that can be transmitted directly and cause severe disease
with high mortality such as ﬁlovirus and henipavirus are
considered World Health Organization (WHO) priority pathogens.
Until the recent West African Ebola virus (EBOV) epidemic, which
resulted in 28,616 conﬁrmed cases and 11,310 deaths,1,2 EBOV
outbreaks were generally small and rapidly contained.3,4 The same
holds true for Nipah (NiV) and Hendra (HeV) viruses, which so far
have mainly caused local clusters of infection,5,6 or small
outbreaks as the one currently ongoing in India.7 However, the
ﬁrst NiV outbreak in Malaysia and Singapore in 1998–1999
resulted in 276 documented infections with a case fatality rate
of approximately 40%,8,9 illustrating the challenges associated
with predicting and preparing for such events. Since licensed
therapies or vaccines are often not immediately available, patient
isolation, supportive care, and contact tracing are the main
approaches used to control these outbreaks.10,11 There is thus a
renewed interest in therapeutic approaches such as convalescent
sera or hyperimmune sera of animal origin, which can be rapidly
available.
Passive antibody treatment with whole blood or plasma from
convalescent patients has been used as experimental therapy
during ﬁlovirus outbreaks since 1967,12,13 with variable results.
Whole blood from convalescent donors was given as a post-
exposure treatment during the 1995 Kikwit outbreak with seven of
eight patients surviving the infection.14 However, post-exposure
treatment of nonhuman primates with whole blood from
convalescent donors did not replicate the successes seen in
human patients.15 More recently, 84 patients treated with
convalescent plasma failed to show signiﬁcant improvement in
survival during the 2014 West African outbreak,16 but deﬁnitive
interpretation of these data is difﬁcult because the antibody titers
and virus-neutralizing activity of the convalescent plasma was not
reported. Post-exposure prophylaxis studies in EBOV-infected
nonhuman primates using high-titer puriﬁed immunoglobulin G
(IgG) from convalescent macaques is fully protective against
subsequent challenge,17 indicating that functional antibody titers
may be the determining factor. Neutralizing antibodies are also
important mediators of protection against NiV.18 Post-exposure
passive transfer of sera from hamsters immunized with either
vaccinia or vesicular stomatitis viruses (VSVs) expressing the NiV-G
protein provides protection from lethal virus challenge in a
hamster model,19,20 as do murine monoclonal antibodies that
bind either NiV-F or NiV-G,21 and a human monoclonal antibody
with neutralizing activity against the related Hendra virus G
protein in ferrets.22
In general, passive immunization has proven to be beneﬁcial for
numerous acute infections and is still commonly used as
emergency treatment against life-threatening diseases. Human
IgG preparations are the gold standard for rabies23 and tetanus24
post-exposure prophylaxis, and are available as emergency
treatment for anthrax.25 Pooled human IgG for intravenous use
(IVIG) is used as a prophylactic and post-exposure treatment
against hepatitis B,26 and is given to patients with complications
during measles infection or to those that are at risk for severe
disease.26
While human convalescent sera may not be readily available in
outbreak situations, antisera of animal origin can be produced in a
short time frame. Animal-origin puriﬁed IgG27 and IgG fragment
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preparations are still routinely used as antivenoms, and even
though immunization of horses with inactivated EBOV failed to
yield effective therapeutic antisera,28 equine hyperimmune sera
produced using EBOV virus-like particles (VLPs) conferred protec-
tion against lethal challenge in rodents.29 Here we compared
different immunization platforms for the rapid induction of high
functional antibody titers against EBOV and NiV, and optimized
the subsequent IgG puriﬁcation process.
RESULTS
Squalene-containing adjuvants enhance EBOV VLP-induced total
and functional antibody titers
VLPs are an effective platform for the display of antigens in their
native conformation.30,31 To assess their ability for induction of
high functional antibody titers, we produced EBOV VLPs by co-
transfecting human embyonic kidney-293 (HEK-293) cells with
plasmids encoding for the EBOV Zaire strain Mayinga matrix
protein (VP40) and the full-length membrane-anchored glycopro-
tein (GP).31 After 48 h, the supernatant was harvested, puriﬁed,
and concentrated via ultracentrifugation. The resulting EBOV VLP
preparation contained two major proteins migrating in
Coomassie-stained gels at 130 kDa and around 40 kDa (Fig. 1a).
Western blot analysis identiﬁed the distinct band at 130 kDa as
EBOV-GP1, the large cleavage fragment of EBOV-GP,31,32 and two
bands between 35 and 55 kDa as two isoforms of EBOV-VP40 due
to a second upstream in-frame start codon33 (Fig. 1b).
To evaluate the effect of adjuvants on total and functional
antibody responses, groups of mice were immunized intramuscu-
larly with 10 μg EBOV VLP alone, or in combination with the
squalene-containing water-in-oil Sigma adjuvant, the oil-in-water
TiterMax adjuvant, or 2% Alhydrogel, all of which are routinely
used for animal immunizations, and boosted 2 and 4 weeks later.
Serum was collected 2 weeks after each immunization and
kinetics of total and neutralizing antibody responses were
followed. First antibodies against EBOV-GP were detected after
2 weeks, with approximately 10-fold higher titers in the Sigma and
TiterMax adjuvant groups. The titers in all groups gradually
increased over the course of the immunizations, but while the
ﬁnal titers induced by non-adjuvanted EBOV VLPs were similar to
those in the Alhydrogel-adjuvanted and TiterMax-adjuvanted
groups, Sigma adjuvant resulted in 10-fold higher ﬁnal titers
(Fig. 1c). Neutralizing antibody titers were determined by plaque
reduction neutralization test (PRNT) with the recombinant VSV
Fig. 1 Ebola VLP production and antibody response kinetics. a, b VLP preparations analyzed after transfection of HEK-293 cells, harvest of the
VLP-containing supernatant, puriﬁcation, and concentration by ultracentrifugation through a sucrose cushion. Samples were separated on
SDS-PAGE gels and proteins were a stained with Coomassie blue or b transferred to PVDF membranes. Blots were stained with a polyclonal
goat antiserum against EBOV. Lane 1: 10 µg VLP sample containing Ebola VP40 and GP; lane 2: 10 µg VLP sample containing only Ebola VP40;
and lane 3: 10 µl negative control (not transfected). All blots were derived from the same experiment and were processed in parallel. c, d Mice
were immunized i.m. with 10 µg of VLPs alone or in combination with either Sigma Adjuvant System, TiterMax Gold, or Alhydrogel, and
boosted 2 and 4 weeks after the ﬁrst immunization. Final serum samples were collected 2 weeks after the second boost. The total antibody
response against recombinant EBOV-GP c and neutralizing antibody response against VSVΔG/EBOV-GP d are shown. Antibodies against
EBOV-GP are reported as reciprocal serum endpoint titers using IPMA and neutralizing antibodies were assessed by the 50% serum
neutralization capacity (PRNT50). Symbols represent the mean of each group (n= 3), and error bars indicate the standard error of the mean.
The Y-axis begins at the detection limit of the respective assays. Statistical signiﬁcance is indicated by *p < 0.05 and **p < 0.01
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that expresses the GP of the closely related EBOV Zaire strain
Kikwit (VSVΔG/EBOV-GP).34 First neutralizing antibodies were
detected after the second immunization, but a robust increase
was only observed in the adjuvanted groups, with a 5-fold
increase in the TiterMax-adjuvanted and Alhydrogel-adjuvanted
groups and a 20-fold increase in the Sigma adjuvant group (Fig.
1d), leading us to choose Sigma adjuvant for all further
experiments.
Induction of robust neutralizing antibody titers requires several
immunizations
VLPs lack the ability for de novo protein production. To determine
the importance of this aspect for the induction of functional
antibodies, we compared adjuvanted EBOV VLPs with vector
vaccines based on the replication-deﬁcient modiﬁed vaccinia
Ankara virus (MVA) that expresses either the GP protein of the
Zaire EBOV Guéckédou strain alone or in combination with VP40
(unpublished data), and the replication-competent VSVΔG/EBOV-
GP.34 Due to the around 80% amino acid sequence identity and
strong structural and functional conservation among Zaire EBOV-
GP proteins, the induced immune responses are cross-reactive
within the species.35,36 As before, mice were immunized three
times in 2-week intervals. Total antibody titers against EBOV-GP
increased rapidly after initial immunization in all groups, but in
contrast to the adjuvanted EBOV VLPs and the VSVΔG/EBOV-GP,
there was no further increase after the third immunization with
the MVA-based viral vectors (Fig. 2a). Neutralizing antibodies were
detected in MVA/EBOV-GP-immunized groups after the ﬁrst and
MVA/EBOV-VP40/GP-immunized groups after the second immu-
nization and slightly increased to yield ﬁnal titers around 10 (Fig.
2b). The ﬁrst neutralizing antibodies in VSVΔG/EBOV-GP animals
were also detected after the ﬁrst immunization with ﬁnal titers
reaching 40 (Fig. 2b). Even though the neutralizing antibodies
were again only detected after the ﬁrst boost in the group
immunized with adjuvanted EBOV VLPs, titers ultimately reached
levels around 100 (Fig. 2b), illustrating that de novo protein
expression is not required for efﬁcient induction of functional
antibodies.
Immunization with adjuvanted EBOV VLPs induces high
neutralizing antibody titers in rabbits
To generate larger volume of antisera for optimization of the
puriﬁcation process and to assess the scalability of antisera
production, we repeated the immunization protocol in rabbits.
Animals were immunized with the adjuvanted EBOV VLPs, MVA/
EBOV-GP, or VSVΔG/EBOV-GP, and boosted 2 and 4 weeks later.
Serum was collected 1 week after the second boost. Total anti-
EBOV-GP antibody titers (Table 1, bottom row) and neutralizing
antibody levels against VSVΔG/EBOV-GP (Table 2, bottom row)
were slightly higher than the titers seen in mice, validating the
immunization scheme in a different species.
To put the titers obtained after immunization of rabbits in a
clinically relevant context, total anti-EBOV antibodies were
quantiﬁed in a validated whole-virion EBOV antibody capture
enzyme-linked immunosorbent assay (ELISA), used to assess the
antibody responses in survivors of EBOV virus disease during the
West African outbreak,37 as well as a virus neutralization assay
(VNT) with EBOV Zaire strain Mayinga used to assess antibody
responses in VSVΔG/EBOV-GP vaccinated volunteers using the
same assay.38 The optical density (OD) values of rabbit sera tested
in the validated whole-virion EBOV ELISA ranged from 3.5 to 4.1
and were thus comparable to high-titer convalescent sera after
patients had cleared the virus.37 Endpoint titrations revealed
comparable total antibody titers against EBOV and EBOV-GP
(Table 1). The neutralizing antibody titers assessed in VNT with
EBOV were for MVA/EBOV-GP rabbit sera more than 10-fold and
for VSVΔG/EBOV-GP and VLP rabbit sera more than 75-fold higher
than the average geometric mean neutralizing endpoint titers of
Fig. 2 Comparison of total and neutralizing antibody responses against EBOV-GP induced in mice using different immunization approaches.
Animals were immunized i.m. with 2 × 105 PFU VSVΔG/EBOV-GP, 1.5 × 108 FFU of either MVA/EBOV-VP40/GP or MVA/EBOV-GP, or 10 µg of
EBOV VLPs in combination with Sigma adjuvant, and boosted 2 and 4 weeks later before ﬁnal serum was collected 2 weeks after the second
boost. The total antibody response against recombinant EBOV-GP a and neutralizing antibody response against VSVΔG/EBOV-GP b are
shown. Antibodies against EBOV-GP are reported as reciprocal serum endpoint titers using IPMA and neutralizing antibodies were assessed by
the 50% serum neutralization capacity (PRNT50). Symbols represent the mean of each group (n= 3), and error bars indicate the standard error
of the mean. The Y-axis begins at the detection limit of the respective assays. Statistical signiﬁcance is indicated by *p < 0.05
Table 1. Comparison of total antibody responses against EBOV and EBOV-GP induced in rabbits using different antigen expression approaches
VSVΔG/EBOV-GP (n= 1) MVA/EBOV-GP (n= 2) 300 µg VLPs+ adjuvant (n= 2)
α-EBOV endpoint titer (log2) (ELISA) 16 14 15
α-EBOV-GP endpoint titer (log2) (IPMA) 16 15 16
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16 (24) or 11 (23.5) in vaccines at day 28 or 180 (Table 2), indicating
that titers of the rabbit hyperimmune sera are within the
therapeutic range.38 While more systematic bridging studies
would be required to directly correlate our in-house with the
ofﬁcial diagnostic assays, the similar relative proportions of the
titers induced by the different immunization platforms indicates
their suitability for initial analyses.
VLP-based antisera production is applicable to other emerging
viral infections
Immunization with recombinant viruses or VLPs containing the
NiV fusion (F) and attachment (G) surface GPs is sufﬁcient to elicit
a protective immune response,20,39,40 and there is considerable
cross-reactivity with different NiV and even Hendra virus strains.41
To evaluate the applicability of the VLP-based immunization
approach for the production of high-titer antisera against other
emerging viruses, NiV VLPs were generated by co-transfecting
HEK-293T cells with plasmids encoding the NiV matrix protein (M)
in combination with either the F or G protein of the NiV Malaysia
strain.42 After 48 h, supernatant was harvested, puriﬁed and
concentrated via ultracentrifugation. The resulting NiV-M/G and
NiV-M/F VLP preparations showed no distinct bands migrating in
Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels (Fig. 3a), but bands correspond-
ing to NiV-M (44 kDa), NiV-G (68 kDa), and two bands representing
uncleaved NiV-F0 and cleaved NiV-F1 (approximately 60 and
48 kDa, respectively) could be readily detected by Western blot
analysis (Fig. 3b).43
To assess the total and functional antibody responses induced
by immunization with the respective NiV GP, two rabbits were
immunized intramuscularly with 300 μg NiV-M/F or NiV-M/G VLPs
in combination with the Sigma adjuvant. Animals were boosted 3
and 5 weeks later and serum was collected before each
immunization and 2 weeks after the second boost to follow the
kinetics of the total and neutralizing antibody responses.
Antibodies against NiV-F in rabbits immunized with NiV-M/F
VLPs were detected after the ﬁrst immunization, while induction
of antibodies against NiV-G required two immunizations with NiV-
M/G VLPs (Fig. 3c). Subsequent immunizations increased total
antibody titers, and titers of NiV-F antibodies ultimately reached
levels approximately two times higher than NiV-G antibodies (Fig.
3c). Consistent with these ﬁndings, neutralizing antibody titers
against the Malaysia strain were found in the NiV-M/F VLP group
after the ﬁrst immunization, while neutralizing antibodies against
NiV-M/G were ﬁrst detected after the second immunization, and
these titers increased in both groups of animals after the third and
fourth immunizations (Fig. 3d). The neutralizing titers against the
NiV-F and NiV-G glycoproteins (approx. 3000) were well above the
level of neutralizing activity (>160 neutralizing units/mL) that
protects against lethal NiV challenge in passive transfer stu-
dies,19,20 which suggests that our rabbit anti-NiV GP sera would
also provide a similar degree of protection.
Multi-step puriﬁcation process yields IgG and F(ab′)2 samples with
high recovery of neutralizing activity
Acute and delayed adverse reactions to antisera, such as
anaphylactic shock and serum sickness, are caused by the
immunogenicity of xenogenic serum proteins or complement
activation by the Fc portion of whole IgG preparations,
respectively.44 To minimize the risk of unwanted side effects, we
established a multi-step puriﬁcation and concentration procedure
using sera from EBOV VLP-immunized rabbits. First, serum
proteins were precipitated in a two-step precipitation using
0.864 and 1.728 M ammonium sulfate followed by IgG afﬁnity
chromatography using Protein A. Next, IgG was modiﬁed by a
pepsin digestion to remove the Fc portion to generate F(ab′)2
preparations (Fig. 4a). To accurately compare antibody titers over
the course of the puriﬁcation process, titers are expressed relative
to the same volume for all samples. The puriﬁcation and
concentration is illustrated on a Coomassie-stained non-reducing
SDS-PAGE gel loaded with the same protein concentration of
initial serum, puriﬁcation intermediates after precipitation, and the
IgG and F(ab′)2 preparations (Fig. 4b). After ammonium sulfate
precipitation, more than 90%, and even after subsequent IgG
afﬁnity puriﬁcation more than 80% of neutralization activity were
recovered (Fig. 4c). Pepsin digest led to around 50% loss of
neutralization activity in F(ab′)2 preparations compared to
unmodiﬁed serum, indicating that the multi-step puriﬁcation
process results in high yield puriﬁed IgG preparations with only
little loss of functional antibody titers, and F(ab′)2 fragmentation
with at least 50% recovery of functional activity.
Comparable in vivo stability of homologous and xenogenic
antibodies in mice
Antibody half-life is an important efﬁcacy determinant of passive
immune therapy. To assess the antibody stability in a different
species, mice were treated intraperitoneally (i.p.) with puriﬁed
homologous mouse IgG, or heterologous rabbit IgG preparations.
Doses were calculated based on total anti-EBOV-GP antibody titers
(Fig. 4d). The antibody levels in recipient mice remained stable
over 9 days after injection regardless of the origin of the IgG, and
treatment with a higher IgG dose resulted in increased detectable
titers in the recipients (Fig. 4d).
Since F(ab′)2 fragments reduce the incidence of adverse events
due to the lack interaction with Fc receptors, they are increasingly
used to treat snake envenomation.45 However, they are associated
with a shorter half-life, which may have a greater impact in the
context of an amplifying virus than a single dose of venom.29 To
determine the stability of the heterologous rabbit F(ab′)2
preparation, we injected mice intraperitoneally with different
doses. In contrast to IgG, F(ab′)2 fragments were only detected on
the ﬁrst day after transfer, even if the higher dose was used (Fig.
4d), indicating that the longer half-life of IgG combined with its
potential side effects may have to be weighed against the lower
stability and reduced activity of F(ab′)2 fragments.
DISCUSSION
The unprecedented magnitude of the Western African EBOV
outbreak resulted in the deployment of novel vaccines and
therapies that were already in advanced stages of clinical
development.46 However, for many other emerging viruses,
development is not that far advanced, so there is a need for
treatment options that can be rapidly produced in clinically
relevant quality and quantities. Here we explored the potential of
generating animal-origin hyperimmune sera in a 2-month time
Table 2. Comparison of neutralizing antibody responses against EBOV and VSVΔG/EBOV-GP induced in rabbits using different antigen expression
approaches
VSVΔG/EBOV-GP (n= 1) MVA/EBOV-GP (n= 2) 300 µg VLPs+ adjuvant (n= 2)
α-EBOV endpoint titer (log2) (VNT) 10 7 10
α- VSVΔG/EBOV-GP titer (log2)(PRNT50) 8 5 8
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frame using EBOV and NiV as model antigens. We found that
adjuvanted VLPs were more effective than MVA-based or VSV-
based expression vectors in inducing high-titer functional
antibodies after repeated immunizations, reaching levels above
the putative protective threshold for the respective pathogen. An
optimized puriﬁcation protocol combining ammonium sulfate
precipitation followed by protein A afﬁnity puriﬁcation yielded
concentrated polyclonal IgG with maintained functional activity
and in vivo stability, indicating that this approach may be feasible
in emergency situations.
Monoclonal antibodies that neutralize EBOV, such as KZ52, are
protective in some small animal models,47 but often fail to provide
protection in more relevant NHP models.48 The success of the
ZMapp monoclonal antibody cocktail demonstrated that targeting
more than one antigenic site, including some non-neutralizing
epitopes, improves efﬁcacy.49 Polyclonal antisera have the
advantage of inherently targeting multiple neutralizing and non-
neutralizing epitopes of a given antigen, thereby reducing the risk
of escape mutant emergence, another known limitation of
monoclonal antibody therapies.50,51 This broader speciﬁcity is
also a unique asset at early stages of an outbreak when the
pathogen is not yet fully characterized, since cross-reactivity of
already available antisera against related strains can be quickly
ascertained and may provide an immediate treatment option.
Even though immunization of horses with inactivated EBOV
failed to produce effective therapeutic antisera,28 more recent
approaches using adjuvanted recombinant EBOV-GP ectodomain
for immunization of sheep led to antisera that were effective as
post-exposure treatment of rodents.52,53 The production of fully
human polyclonal antibodies by immunization of transchromoso-
mal cattle with EBOV-GP nanoparticles constitutes a further
important step,54 but may be limited by availability of these
Fig. 3 Nipah VLP production and antibody response kinetics. a, b VLP preparations analyzed after transfection of HEK-293 cells with NiV-M
and NiV-F protein or NiV-M and NiV-G protein with or without epitope tags, harvest of the VLP-containing supernatant, puriﬁcation, and
concentration by ultracentrifugation through a sucrose cushion. Samples were separated on SDS-PAGE gels and proteins were a stained with
Coomassie blue or b transferred to PVDF membranes. Blots were stained with monoclonal antibodies against the c-myc, HA, and FLAG tags.
Lane 1: 3 µg VLP sample containing NiV-M and NiV-F; lane 2: 3 µg VLP sample containing NiV-Mmyc and NiV-FHA; lane 3: 3 µg VLP sample
containing NiV-M and NiV-G; lane 4: 3 µg VLP sample containing NiV-Mmyc and NiV-GFLAG; lane 5: negative control (not transfected). All blots
were derived from the same experiment and were processed in parallel. c, d Rabbits were immunized i.m. with 300 µg of NiV VLPs containing
either M and F or M and G protein and boosted 3 and 5 weeks after the ﬁrst immunization. Final serum samples were collected 2 weeks after
the second boost. The total antibody response against recombinant NiV-F or NiV-G proteins (c) and neutralizing antibody response against
NiV strain Malaysia (d) are shown. Total antibodies against NiV-F or NiV-G and neutralizing antibodies are reported as reciprocal serum
endpoint titers using IPMA or VNT. Symbols represent the geometric mean of each group (n= 2). The Y-axis begins at the detection limit of
the respective assays
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transgenic animals. By comparing the replication-competent
recombinant VSV and the replication-incompetent MVA vaccine
platforms with adjuvanted VLPs, we show that even though de
novo antigen expression was associated with an earlier
development of total anti-EBOV antibodies, functional titers
increased over the course of the immunizations for all candidates,
with adjuvanted VLPs resulting in induction of similar ﬁnal titers as
VSVΔG/EBOV-GP. This indicates that not de novo antigen
Fig. 4 Puriﬁcation and characterization of IgG and F(ab′)2 preparations. Antiserum from rabbits immunized three times with VLP-adjuvant
combination was collected 1 week after the ﬁnal boost. a Overview of the puriﬁcation process showing two-step precipitation with 20 and
40% ammonium sulfate saturation, buffer exchange, and desalting, followed by IgG isolation using protein A afﬁnity chromatography, and F
(ab′)2 preparation by pepsin digest. Intermediates and ﬁnal preparations were resuspended at an initial volume or appropriately concentrated.
b Protein analysis of puriﬁcation intermediates. Ten micrograms of total protein from each preparation was separated by non-reducing SDS-
PAGE and stained with Coomassie blue. Lane 1: initial antiserum; lane 2: resuspended proteins following 20–40% precipitation; lane 3: elution
of protein A afﬁnity chromatography; and lane 4: IgG after pepsin digest. Total protein concentrations assessed by BCA assay are shown below
SDS-PAGE. All blots were derived from the same experiment and were processed in parallel. c Neutralizing antibody response against VSVΔG/
EBOV-GP of initial antiserum (n= 4), intermediate after precipitation (n= 4), afﬁnity-puriﬁed IgG (n= 4), and F(ab′)2 preparation of afﬁnity-
puriﬁed IgG (n= 2) was assessed by the 50% serum neutralization capacity (PRNT50). Bars represent the mean of each group, and error bars
indicate the standard error of the mean. d Mice received single doses of either puriﬁed homologous mouse IgG or heterologous rabbit IgG or
F(ab′)2 preparation by i.p. injection. Detection of α-EBOV-GP antibodies is reported as the reciprocal serum endpoint titers with the use of
VSVΔG/EBOV-GP in an IPMA assay. Symbols represent single animals and the corresponding lines for each group indicate the geometric mean
(n= 3). The Y-axis begins at the detection limit of the respective assay
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expression but repeated exposure to the antigen in its native
conformation is required for the induction of high functional
antibody titers.
The strong neutralizing antibody responses seen after immu-
nization with adjuvanted VLPs not only against EBOV but also NiV
demonstrates the potential of this approach to be extended to
other emerging pathogens. The determinants of VLP formation in
other virus families such as ﬂaviviruses,55 coronaviruses,56 and
orthomyxoviruses57 are known, and medium-scale to large-scale
transient transfection processes are increasingly used for custo-
mized antigen or protein production.58 This could conceivably
form the basis of a “plug-and-play” system where antigens from
emerging viruses are either synthesized or cloned, then expressed
and puriﬁed using such production processes, and used for
immunization of serum-producing animals. The regulatory
requirements regarding the quality and safety of antigens and
adjuvants used for the production of antisera differ considerably
from vaccines,59,60 as they are not applied directly to patients.
Since the manufacturing of therapeutic antisera is antigen-
independent, existing processes and facilities could be used with
little or no further adaptation to produce such pathogen-speciﬁc
antisera in an emergency situation. Furthermore, for pathogens
with the potential of high public health impact, licensing under
the Food Drug Administration “Animal Rule” or the EMA “Orphan
Medicines” designation and subsequent stockpiling could be
envisaged.61,62
VLPs have long been licensed as hepatitis B or human
papillomavirus vaccines,63 and they are among the candidate
platforms for emerging infections.64 For the generation of
therapeutic antisera, VLPs combine several advantages: they are
non-infectious and can thus be handled without biosafety
concerns, they can be adjuvanted, they are boostable, and they
can be produced in a variety of cell lines.65,66 For EBOV, the
combination of a non-neutralizing antibody targeting the glycan
cap makes the monoclonal antibody cocktail ZMapp more
potent,49 indicating that the native glycosylation proﬁle could
be one crucial factor in the induction of effective polyclonal
antibodies. In general, mammalian expression systems are able to
produce post-translational modiﬁcations (PTMs), but only human
cell lines have the advantage of producing complex proteins with
fully human PTMs that are similar to those naturally synthetized in
humans.67 A recent report demonstrates the efﬁcacy of polyclonal
antisera generated by immunization with VLPs produced in an
insect cell expression system.29 However, differences in N-
glycosylation and O-glycosylation proﬁle between human and
insect cell derived ﬁlovirus GPs were reported,68 and may affect
the quality of the antisera, and limit the application of this system
to other pathogens.
After multiple-step puriﬁcation we observed similar in vivo
stability for xenogenic rabbit IgG and homologous mouse IgG
preparations in recipient mice, while rabbit F(ab′)2 was only
detectable for 1 day after transfer. This short half-life of F(ab′)2
preparations was also observed in earlier studies where a single
dose of antisera resulted in better protection over a longer period
compared to repeated treatment with F(ab′)2 fragments.
29 Until
processes to stabilize F(ab′)2 preparations have been developed,
full IgG with its known and controllable risks for adverse events
may be a valuable addition to the toolbox against newly emerging
infectious diseases.
MATERIALS AND METHODS
Cells and viruses
Vero E6 cells (ATCC CRL-1586), MDCK cells (ATCC CCL-34) and HEK-293
cells (ATCC CRL-1573) were maintained at 37 °C and 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 5%
(v/v) fetal bovine serum (FBS, Invitrogen) and 200mM L-glutamine (Sigma-
Aldrich).
The recombinant vesicular stomatitis expressing the GP derived from
Zaire EBOV isolate Kikwit in place of the original VSV GP (VSVΔG/EBOV-
GP)34 as well as the Zaire EBOV strains Makona and Mayinga, and the NiV
strain Malaysia were grown on Vero E6 cells. The viral titers of the Zaire
EBOV and NiV strains were determined by limited dilution, using
cytopathic effect (CPE) as read out. VSVΔG/EBOV-GP was concentrated
by centrifugation for 1 h at 100,000 × g and 4 °C through a 20% (w/v)
sucrose cushion and resuspended in DMEM or in phosphate-buffered
saline (PBS) for immunizations. Viral titers were determined by plaque
assay using Avicel RC-591 overlay (FMC Corporation). Brieﬂy, 200 µl/well of
10-fold serial virus dilutions in DMEM were added to Vero E6 cells in 12-
well tissue culture plates. For the overlay, 3% Avicel in PBS was mixed with
an equal volume of DMEM with 5% FBS. After incubation for 1 h at room
temperature with gentle agitation, 2 ml/well of 1.5% Avicel overlay was
added, and plates were incubated at 37 °C for 48 h. For visualization of the
plaques, 1 ml/well PBS containing 10% crystal violet, 12.5% paraformalde-
hyde (PFA), and 25% methanol was added and incubated for 30min at
room temperature, and titers were expressed as plaque-forming units
(PFUs).
The MVA vector vaccines delivering either the GP from Zaire EBOV strain
Guéckédou 2014 alone (MVA/EBOV-GP) or together with the EBOV-VP40
matrix protein (MVA/EBOV-VP40/GP) were produced by virus ampliﬁcation
in secondary chicken embryo ﬁbroblasts, puriﬁed by ultracentrifugation
through sucrose, and reconstituted in Tris-buffered saline (pH 7.4). The
vaccine preparations were stored at −80 °C before use. All quality control
experiments were essentially performed as described previously.69 Vaccine
preparations were titrated by plaque assay using MVA-speciﬁc immunos-
taining, and titers were indicated in focus-forming units (FFUs).
Expression plasmids and VLP production
The construction of mammalian expression plasmids encoding the VP40
matrix protein (pCAGGS-EBOV/VP40) or the GP (pCAGGS-EBOV/GP) of the
Zaire EBOV strain Mayinga have been described previously.70,71 Expression
plasmids encoding the matrix protein M (pCG-NiV/M and pCG-NiV/Mmyc),
the GP for fusion F (pCG-NiV/F and pCG-NiV/FHA) or attachment G (pCG-
NiV/G and pCG-NiV/GFLAG) of the NiV strain Malaysia have also been
reported.42 For production of EBOV VLPs, HEK-293 cells at approximately
80% conﬂuency were seeded in 175 cm2 tissue culture ﬂasks and co-
transfected with 20 µg of each of the plasmids mixed with four volumes of
18mM polyethylenimine reagent (Sigma-Aldrich).70 For production of NiV
VLPs, cells were transfected with 20 µg of plasmid DNA encoding for the M
or Mmyc protein and 20 µg of plasmid DNA encoding for either the F, FHA,
G, or GFLAG proteins. Transfection mixtures were prepared in DMEM
without additives. After incubation at 37 °C for 12 h, the medium was
changed, and the cells were incubated for another 48 h. Culture
supernatants were harvested and clariﬁed by centrifugation at 2000 × g
for 10 min at 4 °C. VLPs were then pelleted by ultracentrifugation through a
20% (w/v) sucrose cushion for 3 h for EBOV VLPs or 2 h for NiV VLPs
at 100,000 x g and 4 °C, and pellets were resuspended in PBS and stored
at 4 °C.
Quantiﬁcation of total antibodies
Total antibody responses were determined by immunoperoxidase mono-
layer assay (IPMA). Brieﬂy, for determination of EBOV-GP-speciﬁc anti-
bodies 5 × 105 Vero E6 cells were seeded in 96-well plates and infected
with 100 PFU VSVΔG/EBOV-GP. For determination of NiV-F-speciﬁc and
NiV-G-speciﬁc antibody responses, MDCK cells were transfected with 20 µg
DNA of either pCG-NiV/FHA or pCG-NiV/GFLAG plasmids. Cells were
incubated for 48 h at 32 °C before ﬁxation with 2% PFA. Serial 2-fold
dilutions of antisera were added to the ﬁxed cells and incubated for 2 h at
room temperature, followed by incubation with horseradish peroxidase
(HRP)-coupled secondary antibody, and visualized by staining with 3-
amino-9-ethylcarbazole (Sigma-Aldrich). Total antibody titers were calcu-
lated as geometric mean of the reciprocal of the last serum dilution at
which positive staining was detected.
Total antibody responses against whole EBOV virus were determined by
ELISA as described previously.37,38 Brieﬂy, particles of the Zaire EBOV
isolate Makona were puriﬁed and concentrated by ultracentrifugation
through a 20% sucrose cushion, and the pellet was resuspended in PBS
containing 1% SDS and inactivated by boiling for 10min. ELISA plates were
then coated with inactivated Zaire EBOV isolate Makona, and rabbit
antisera were added at the respective dilution and detected by a
polyclonal HRP-coupled secondary antibody. After staining with TMB
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(KPL Inc.) and addition of the stop solution (KPL Inc.), the OD was
measured at 450–630 nm. Each sample was analyzed in duplicate and the
mean OD values were corrected by subtracting mock OD values from
values obtained by incubating the same serum with EBOV antigen. For
endpoint titrations, serial 2-fold serum dilutions were added to coated
ELISA plates. Each sample was analyzed in duplicate and the mean OD
values were corrected as described above. The cut-off was calculated as
the mean plus standard deviation (SD) multiplied with 10 (mean ± SD × 10)
of negative rabbit sera and the total antibody titers were expressed as the
reciprocal of the highest serum dilution yielding an OD value greater than
the cut-off OD of 0.120.
Quantiﬁcation of neutralizing antibodies
To measure neutralizing antibodies, a VSVΔG/EBOV-GP-based PRNT assay
or a virus neutralization assay with Zaire EBOV isolate Mayinga was used.
For PRNT, 2-fold serial dilutions of heat-inactivated antisera in DMEM were
mixed with the appropriate volume of 103 PFU/ml VSVΔG/EBOV-GP to
result in a ﬁnal concentration of 102 PFU/well. The mixture was incubated
at room temperature for 30min, and then 200 µl/well was added to
conﬂuent 12-well dishes of Vero E6 cells. After incubation for 1 h at room
temperature with gentle agitation, the inoculum was removed and
replaced with 2ml 1.5% Avicel overlay. Plates were incubated at 37 °C
and for 48 h, and plaques were visualized using crystal violet staining. The
PRNT50 titer was calculated by averaging the reciprocal of the highest
serum dilution reducing the number of plaques by 50% relative to the
average number of plaques in positive control wells.
The virus neutralization assay for EBOV was performed as described
previously.38 Brieﬂy, serial 2-fold dilutions of heat-inactivated rabbit
antisera preparations were incubated with 102 50% tissue culture infection
doses (TCID50) of Zaire EBOV isolate Mayinga, and then added to Vero E6
cells. The CPE was evaluated after 7 days and titers are expressed as the
geometric mean of the reciprocal of the last serum dilution at which CPE
was observed.
For the virus neutralization assay of NiV antisera 2-fold serial dilutions of
the rabbit sera in 96-well plates were mixed with 102 TCID50 NiV strain
Malaysia. The virus and serum dilutions were incubated for 1 h at 37 °C,
after which Vero E6 cells were added to each well. The CPE was assessed
after 6 days, and neutralizing titers are reported as the geometric mean of
four replicates.
All experiments with infectious EBOV or NiV were performed in the BSL4
facility of the Institute of Virology, Philipps-University Marburg, in
compliance with German regulations.
Immunizations and serum transfer study
All animal experiments were carried out in compliance with the regulations
of German animal protection laws and authorized by the Regierung-
spräsidium Darmstadt, Germany. Balb/c mice were purchased from Janvier
S.A.S. and New Zealand White rabbits from Charles River Germany.
To generate mouse antisera, groups of 6-week-old Balb/c mice were
immunized intramuscularly with either 2 × 105 PFU of VSVΔG/EBOV-GP,
1.5 × 108 PFU of either MVA/EBOV-VP40/GP or MVA/EBOV-GP, or 10 µg of
EBOV VLPs mixed in a 1:1 ratio (v/v) with either Sigma Adjuvant System
(0.5 mg monophosphoryl lipid A (detoxiﬁed endotoxin) from Salmonella
minnesota and 0.5 mg synthetic trehalose dicorynomycolate in 2%
squalene-Tween-80-water, Sigma), or TiterMax Gold (block polymer CRL-
8300, squalene, and sorbitan monooleate, Sigma), or 2% Alhydrogel
(Invivogen). All animals were boosted two and 4 weeks after the ﬁrst
immunization. Three mice from each immunization approach were
sacriﬁced at 0, 14, 28, and 42 days post-immunization and blood was
collected by cardiac puncture.
For generation of rabbit EBOV antisera, New Zealand White rabbits were
immunized intramuscularly with either 1 × 108 PFU of VSVΔG/EBOV-GP,
5 × 109 PFU MVA/EBOV-GP, or 300 µg of EBOV VLPs mixed in a 1:1 ratio (v/
v) with Sigma Adjuvant System, and boosted 2 and 4 weeks later. Blood
samples were collected from the marginal ear vein on days 0, 14, and 28,
and animals were sacriﬁced 35 days post-immunization by exsanguination.
For generation of NiV-F or NiV-G antisera, New Zealand White rabbits were
immunized intramuscularly with 300 µg of NiV VLPs containing either NiV-
M/F or NiV-M/G mixed in a 1:1 ratio (v/v) with Sigma Adjuvant System, and
boosted 3 and 5 weeks later. Blood samples were collected from the
marginal ear vein on days 0, 21, and 35, and animals were sacriﬁced
49 days post-immunization by exsanguination.
To test the stability of the respective antisera in a xenogenic transfer
model, 6-week-old Balb/c mice were administered 200 µl of puriﬁed mouse
or rabbit IgG, or rabbit F(ab′)2 fragment by intraperitoneal injection. Three
mice from each antiserum transfer group were sacriﬁced at days 1, 3, 6,
and 9 after transfer and blood was collected by exsanguination. The rabbit
sera were tested for total antibodies against EBOV-GP by IPMA.
Antisera puriﬁcation and fragmentation
IgG was puriﬁed from rabbit antisera using a multi-step process. First,
animal sera were treated with 0.864 M (20% saturation) ammonium sulfate
(Pierce) at 4 °C for 6 h to remove serum proteins that are less soluble than
IgG. Precipitated proteins were removed by centrifugation at 3000 × g for
20min at 4 °C. Next, the ammonium sulfate concentration of the
supernatant was adjusted to 1.944 M (45% saturation) to remove serum
proteins that are more soluble than IgG. After centrifugation, the
supernatant was removed and the IgG-containing precipitate was
dissolved in the original volume of the serum sample using 0.1 M Tris-
HCl. The dissolved precipitate was dialyzed against Tris-buffered saline
through a 20 kDa molecular weight cut-off (MWCO) cassettes (Thermo
Scientiﬁc) before IgG was puriﬁed by afﬁnity chromatography using
protein A columns (Vivapure Kit, Sartorius) according to the manufacturer’s
recommendations with some modiﬁcations. Brieﬂy, 5 ml precipitated
sample was mixed with two volumes of 1.5 M glycine/NaOH, 3 M NaCl,
pH 9.0, binding buffer and centrifuged at 150 × g for 30 min at room
temperature to let the IgG bind to protein A. This step was repeated with
the ﬂow through before the column was washed eight times with binding
buffer and centrifuged at 500 × g for 3 min at room temperature. IgG was
eluted in 10ml 0.2 M glycine/HCl elution buffer with pH 2.5 immediately
into 1.3 ml previously prepared 1 M Tris-HCl, pH 9.0, neutralization buffer to
bring the samples’ pH to approximately 7.5. For concentrating to the
original volume and buffer exchange of the IgG sample, 50 kDa MWCO
centrifugal column (Vivaspin, Sartorius) were used according to the
manufacturer’s recommendations. Concentrated IgG was dissolved in PBS
for immunization, or 20mM sodium acetate buffer, pH 4 for F(ab′)2
preparation. To generate F(ab′)2 fragments, puriﬁed IgG in acetate buffer
was mixed with pepsin (>2500 U/mg, Sigma) in a 40:1 ratio and incubated
at 37 °C for 6 h. The digestion was stopped with the addition of Tris base
(pH 11.24) to adjust the ﬁnal pH to 7.4. F(ab′)2 fragments were separated
from undigested IgG by separation through a 100 kDa MWCO centrifugal
concentrator and from remaining peptides and pepsin by separation
through a 50 kDa MWCO centrifugal concentrator before dissolving in PBS.
SDS-PAGE and Western blot analysis
The protein concentration of puriﬁed VLPs was determined by Bradford
assay (Bio-Rad), and the BCA assay (Thermo Fisher) was used for samples of
the serum puriﬁcation process. For veriﬁcation of sample quality and
purity, EBOV VLP samples containing 10 µg total protein or NiV VLP
samples containing 3 µg total protein were separated by 10% reducing
SDS-PAGE and antiserum samples containing 10 µg total protein were
separated by 8% non-reducing SDS-PAGE and stained with Coomassie
blue (Fisher Bioreagents) or transferred to polyvinylidene diﬂuoride (PVDF)
membranes (Millipore) for Western blot analysis. Blots were stained with a
polyclonal goat antiserum against EBOV virus72 at a working solution of
1:1000 or monoclonal antibodies against FLAG-tag, HA-tag, or c-myc-tag
(all Sigma) at the recommended dilution to detect the respective epitope-
tagged NiV proteins.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 on log-
transformed data using multiple comparison analysis of the ﬁnal mouse
sera in one-way analysis of variance with Tukey's post-test. Signiﬁcance
was considered at p values ≤0.05.
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